Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy

Contributed by: Business Wire

Logo

Tags

Health

Hospitals

Neurology

Clinical Trials

Pharmaceutical

Biotechnology

NGF

More Like This

Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program

Ferrer's pharmaceutical production plant in Sant Cugat del Valles, Barcelona, Spain.

Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule

Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial

PR Newswire associated0

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

PR Newswire associated0

Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs

Ferrer's pharmaceutical production plant in Sant Cugat del Vallés, Barcelona, Spain.

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

PR Newswire associated0

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

TreeFrog Therapeutics 10L bioreactor for cell therapy (Photo credits: TreeFrog Therapeutics)

TreeFrog Publishes Results of First Successful Bioproduction of a Parkinson’s Disease Cell Therapy in Scalable Bioreactor in Neurotherapeutics Journal